Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Business Wire
More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of B-cell malignanciesNew data demonstrate potential of epcoritamab in first and second-line settings in follicular lymphoma (FL) and first-line in diffuse large B-cell lymphoma (DLBCL)Results from Phase 3 EPCORE FL-1 trial, evaluating epcoritamab in combination with rituximab and lenalidomide (R2) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) accepted for oral presentation COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin’s lymphoma (NHL) subtypes, will be presented at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Assessing Genmab (CPSE:GMAB) Valuation After Its Recent Share Price Strength [Yahoo! Finance]Yahoo! Finance
- Genmab (GMAB) Q3 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout [Seeking Alpha]Seeking Alpha
- Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]Yahoo! Finance
- Genmab (CPSE:GMAB) Valuation in Focus After Recent Share Price Pullback [Yahoo! Finance]Yahoo! Finance